Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German Expert Consensus Panel with focus on cardiovascular management

zu Verbundenen Objekten

Abstract: Treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia (Ph+ ALL) has been revolutionized with the advent of tyrosine kinase inhibitors (TKIs). Most patients with CML achieve long-term survival similar to individuals without CML due to treatment with TKIs not only in frontline but also in further lines of therapy. The third-generation TKI ponatinib has demonstrated efficacy in patients with refractory CML and Ph+ ALL. Ponatinib is currently the most potent TKI in this setting demonstrating activity against T315I mutant clones. However, ponatinib’s safety data revealed a dose-dependent, increased risk of serious cardiovascular (CV) events. Guidance is needed to evaluate the benefit–risk profile of TKIs, such as ponatinib, and safety measures to prevent treatment-associated CV events. An expert panel of German hematologists and cardiologists summarize current evidence regarding ponatinib’s efficacy and CV safety profile. We propose CV management strategies for patients who are candidates for ponatinib

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
Acta haematologica. - 143, 3 (2020) , 217-231, ISSN: 1421-9662

Schlagwort
Chronisch-myeloische Leukämie

Ereignis
Veröffentlichung
(wo)
Freiburg
(wer)
Universität
(wann)
2020
Urheber

DOI
10.1159/000501927
URN
urn:nbn:de:bsz:25-freidok-1660298
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:52 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

Entstanden

  • 2020

Ähnliche Objekte (12)

Novel approaches in myelofibrosis

Novel approaches in myelofibrosis

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management

Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management

Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management

Diagnostik und Therapie der Polycythaemia vera im Jahre 2015

Diagnostik und Therapie der Polycythaemia vera im Jahre 2015

Diagnostik und Therapie der Polycythaemia vera im Jahre 2015

Diagnostik und Therapie der Polycythaemia vera im Jahre 2015

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML)

Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML)

Elucidating the complexity of the interferon alpha response and clonal heterogeneity in polycythemia vera patients using single-cell RNA sequencing

Elucidating the complexity of the interferon alpha response and clonal heterogeneity in polycythemia vera patients using single-cell RNA sequencing

Influence of the JAK2-V617F mutation on integrin-mediated adhesion to VCAM1 in murine and human cell lines in the context of classical Philadelphia-negative myeloproliferative neoplasms

Influence of the JAK2-V617F mutation on integrin-mediated adhesion to VCAM1 in murine and human cell lines in the context of classical Philadelphia-negative myeloproliferative neoplasms

Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms: implications from the German study group for MPN bioregistry

Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms: implications from the German study group for MPN bioregistry

Verbundene Objekte